ArticleAnnals of medicine2025
Lymphocyte-to-C-reactive protein ratio predicts prognosis in unresectable locally advanced non-small cell lung cancer patients.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Development and validation of a composite C-reactive protein-to-albumin ratio-tumor-node-metastasis index for prognostic stratification in gastric cancer: A multicenter cohort study.The Journal of international medical research · 2026Article
- Periodontitis as a potential predisposing factor for gallstone cholecystitis: exploring the role of chronic systemic inflammation.Surgery today · 2026Observational
- Prognostic value of inflammatory markers and different treatment regimens in neuroendocrine cervical carcinoma: a retrospective study.Frontiers in pharmacology · 2025Article
- Association of the lymphocyte-to-C-reactive protein ratio with long-term mortality in hospitalized older adults with severe dysphagia.Frontiers in nutrition · 2025Article
- An Emergency-deployable Albumin-enhanced NLR Derived by Machine Learning Improves Risk Stratification in Lung Cancer: A Multicenter Cohort Study.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe lymphocyte-to-C-reactive protein ratio (LCR) is a promising inflammation-based tool for assessing the status of patients with malignant tumours. This study evaluated the ability of LCR to predict the prognosis of patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC) after chemoradiotherapy.
methodsWe retrospectively investigated 206 consecutive patients with unresectable LA-NSCLC who underwent chemoradiotherapy between January 2016 and November 2019. The LCR was calculated from the differential count by dividing the absolute lymphocyte count by the C-reactive protein level. The optimal cut-off value of LCR was determined using the receiver operating characteristic (ROC) curve, and the enrolled patients were divided into two groups for further analysis according to LCR. Overall survival (OS) and disease-free survival (DFS) were assessed using univariate and multivariate Cox regression analyses.
resultsIn patients with unresectable LA-NSCLC, the level of LCR was significantly associated with pathology (
conclusionLCR is a promising prognostic index in patients with LA-NSCLC undergoing chemoradiotherapy, and an increase in the LCR level contributes to better outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.